Key Drivers
- Strong liquidity
- Widening losses
- Elevated multiples
AIAI Summary
GKOS is shifting from a lumpy device business to a high‑margin, recurring‑revenue therapeutics/medtech growth story—if iDose re‑administration uptake and broad payer coverage for Epioxa materialize the company can convert guidance into durable profits, but the current valuation already prices that execution/reimbursement outcome so any delays or unfavorable coverage would sharply erode the thesis.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Widening losses
- •Elevated multiples
GKOS has strong liquidity and low leverage but is running large operating/net losses, negative EBITDA/FCF and widening quarterly deterioration while the market still prices a premium.
Price Behavior
Key Price Behavior Insights:
- •Downtrend momentum
- •Elevated volatility
- •Resistance cap
Stock downtrend: price fell ~16% over the last month to $100.99, trading ~8% below its last-month average with elevated short-term volatility, testing support at $97.02 and capped by resistance near $119–$121.
~16% decline over the last month with a 21-day
Sentiment & News
Key News Insights:
- •Epioxa launch
- •Stock weakness
- •Mixed ownership
Glaukos launched FDA‑approved Epioxa™, a potential long‑term growth driver for corneal treatments even as the stock has seen notable near‑term selling and mixed institutional/insider moves.
The Epioxa commercial rollout should support longer‑term revenue upside, but near‑term price pressure and investor repositioning may keep volatility elevated
Similar Companies in Healthcare
Other companies in the same sector with AI ratings